hydroxychloroquin
less
toxic
deriv
chloroquin
effect
inhibit
infect
vitro
jia
liu
ruiyuan
cao
mingyu
xu
xi
wang
huanyu
zhang
hengrui
hu
yufeng
li
zhihong
hu
wu
zhong
manli
wang
dear
editor
outbreak
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
pose
seriou
threat
global
public
health
local
economi
march
case
confirm
china
includ
death
well
confirm
case
countri
huge
number
infect
dead
peopl
call
urgent
demand
effect
avail
afford
drug
control
diminish
epidem
recent
report
two
drug
remdesivir
chloroquin
cq
phosphat
effici
inhibit
infect
vitro
remdesivir
nucleosid
analog
prodrug
develop
gilead
scienc
usa
recent
case
report
show
treatment
remdesivir
improv
clinic
condit
first
patient
infect
unit
state
phase
iii
clinic
trial
remdesivir
launch
wuhan
februari
howev
experiment
drug
remdesivir
expect
larg
avail
treat
larg
number
patient
time
manner
therefor
two
potenti
drug
cq
appear
drug
choic
largescal
use
due
avail
proven
safeti
record
rel
low
cost
light
preliminari
clinic
data
cq
ad
list
trial
drug
guidelin
diagnosi
treatment
sixth
edit
publish
nation
health
commiss
peopl
republ
china
cq
long
use
treat
malaria
amebiasi
howev
plasmodium
falciparum
develop
widespread
resist
develop
new
antimalari
becom
choic
prophylaxi
malaria
addit
overdos
cq
caus
acut
poison
death
past
year
due
infrequ
util
cq
clinic
practic
product
market
suppli
greatli
reduc
least
china
hydroxychloroquin
hcq
sulfat
deriv
cq
first
synthes
introduc
hydroxyl
group
cq
demonstr
much
less
toxic
cq
anim
importantli
hcq
still
wide
avail
treat
autoimmun
diseas
system
lupu
erythematosu
rheumatoid
arthriti
sinc
cq
hcq
share
similar
chemic
structur
mechan
act
weak
base
immunomodul
easi
conjur
idea
hcq
may
potent
candid
treat
infect
actual
februari
seven
clinic
trial
registri
found
chines
clinic
trial
registri
http
wwwchictrorgcn
use
hcq
treat
whether
hcq
efficaci
cq
treat
infect
still
lack
experiment
evid
end
evalu
antivir
effect
hcq
infect
comparison
cq
vitro
first
cytotox
hcq
cq
african
green
monkey
kidney
cell
measur
standard
assay
result
show
author
open
access
articl
licens
creativ
common
attribut
intern
licens
permit
use
share
adapt
distribut
reproduct
medium
format
long
give
appropri
credit
origin
author
sourc
provid
link
creativ
common
licens
indic
chang
made
imag
third
parti
materi
articl
includ
articl
creativ
common
licens
unless
indic
otherwis
credit
line
materi
materi
includ
articl
creativ
common
licens
intend
use
permit
statutori
regul
exce
permit
use
need
obtain
permiss
directli
copyright
holder
view
copi
licens
visit
http
fig
better
compar
antivir
activ
cq
versu
hcq
doserespons
curv
two
compound
determin
four
differ
multipl
infect
moi
quantif
viral
rna
copi
number
cell
supernat
h
post
infect
pi
data
summar
fig
supplementari
tabl
show
moi
maxim
effect
concentr
ec
cq
lower
hcq
differ
ec
valu
statist
signific
moi
p
moi
p
supplementari
tabl
worth
note
ec
valu
cq
seem
littl
higher
previou
report
moi
like
due
adapt
viru
cell
cultur
significantli
increas
viral
infect
upon
continu
passag
consequ
select
index
si
cc
ec
cq
higher
hcq
moi
respect
result
corrobor
immunofluoresc
microscopi
evidenc
differ
express
level
viru
nucleoprotein
np
indic
drug
concentr
h
pi
supplementari
fig
taken
togeth
data
suggest
activ
hcq
seem
less
potent
compar
cq
least
certain
moi
cq
hcq
weak
base
known
elev
ph
acid
intracellular
organel
endosomeslysosom
essenti
membran
fusion
addit
cq
could
inhibit
sarscov
entri
chang
glycosyl
receptor
spike
protein
timeofaddit
experi
confirm
hcq
effect
inhibit
entri
step
well
postentri
stage
also
found
upon
cq
treatment
supplementari
fig
explor
detail
mechan
action
cq
hcq
inhibit
viru
entri
coloc
virion
earli
endosom
ee
endolysosom
el
analyz
immunofluoresc
analysi
ifa
confoc
microscopi
quantif
analysi
show
min
pi
untreat
cell
intern
virion
antinp
red
observ
earli
endosom
antigen
posit
ee
green
virion
transport
late
endosomallysosom
protein
el
green
n
cell
group
contrast
presenc
cq
hcq
significantli
virion
cq
hcq
p
detect
ee
virion
cq
hcq
p
found
coloc
el
n
cell
fig
c
suggest
cq
hcq
block
transport
ee
el
appear
requir
releas
viral
genom
case
sarscov
interestingli
found
cq
hcq
treatment
caus
notic
chang
number
sizemorpholog
ee
el
fig
untreat
cell
ee
much
smaller
el
fig
cqand
hcqtreat
cell
abnorm
enlarg
ee
vesicl
observ
fig
arrow
upper
panel
mani
even
larger
el
untreat
cell
agreement
previou
report
treatment
cq
induc
format
expand
cytoplasm
vesicl
within
ee
vesicl
virion
red
local
around
membran
green
vesicl
cq
treatment
caus
obviou
chang
number
size
el
howev
regular
vesicl
structur
seem
disrupt
least
partial
contrast
hcqtreat
cell
size
number
el
increas
significantli
fig
arrow
lower
panel
sinc
acidif
crucial
endosom
matur
function
surmis
endosom
matur
might
block
intermedi
stage
endocytosi
result
failur
transport
virion
ultim
releas
site
cq
report
elev
ph
see
figur
previou
page
fig
compar
antivir
efficaci
mechan
action
cq
hcq
infect
vitro
cytotox
antivir
activ
cq
hcq
cytotox
two
drug
vero
cell
determin
assay
vero
cell
treat
differ
dose
either
compound
pb
control
h
infect
moi
viru
yield
cell
supernat
quantifi
qrtpcr
h
pi
yaxi
repres
mean
percent
inhibit
normal
pb
group
experi
repeat
twice
b
c
mechan
cq
hcq
inhibit
viru
entri
vero
cell
treat
cq
hcq
h
follow
viru
bind
moi
h
unbound
virion
remov
cell
supplement
fresh
drugcontain
medium
min
fix
stain
ifa
use
antinp
antibodi
virion
red
antibodi
ee
green
el
green
nuclei
blue
stain
hoechst
dye
portion
virion
coloc
ee
el
group
n
cell
quantifi
shown
b
repres
confoc
microscop
imag
viral
particl
red
ee
green
el
green
group
display
c
enlarg
imag
box
indic
singl
vesiclecontain
virion
arrow
indic
abnorm
enlarg
vesicl
bar
statist
analysi
perform
use
oneway
analysi
varianc
anova
graphpad
prism
f
df
p
lysosom
knowledg
lack
studi
impact
hcq
morpholog
ph
valu
endosom
lysosom
observ
suggest
mode
action
cq
hcq
appear
distinct
certain
aspect
report
oral
absorpt
cq
hcq
human
effici
anim
drug
share
similar
tissu
distribut
pattern
high
concentr
liver
spleen
kidney
lung
reach
level
time
higher
plasma
report
safe
dosag
mgkg
per
day
hcq
sulfat
could
gener
serum
level
human
therefor
safe
dosag
hcq
concentr
tissu
like
achiev
inhibit
infect
clinic
investig
found
high
concentr
cytokin
detect
plasma
critic
ill
patient
infect
suggest
cytokin
storm
associ
diseas
sever
direct
antivir
activ
hcq
safe
success
antiinflammatori
agent
use
extens
autoimmun
diseas
significantli
decreas
product
cytokin
particular
proinflammatori
factor
therefor
patient
hcq
may
also
contribut
attenu
inflammatori
respons
conclus
result
show
hcq
effici
inhibit
infect
vitro
combin
antiinflammatori
function
predict
drug
good
potenti
combat
diseas
possibl
await
confirm
clinic
trial
need
point
although
hcq
less
toxic
cq
prolong
overdos
usag
still
caus
poison
rel
low
si
hcq
requir
care
design
conduct
clinic
trial
achiev
effici
safe
control
infect
